In short
Clinical trials are investigating Asp1570 in adults with advanced solid tumors. The studies are looking at safety, tolerability, and the best dose, both when Asp1570 is used alone and when it is combined with pembrolizumab or standard therapies.
Key points
- Asp1570 is being studied in adults with advanced solid tumors. The listed trial is a Phase 1/2 study, which means it is an early trial focused on safety and dose finding. Researchers are testing Asp1570 alone and also with pembrolizumab, standard therapies, or both. The main goals are to check safety, tolerability, and to find the recommended dose or maximum tolerated dose. The trial also measures side effects, lab test changes, vital signs, and ECG results. The study was completed and enrolled 310 people.
Trial overview
The listed study, NCT05083481, tested Asp1570 in adults with advanced solid tumors. It was an interventional trial, which means the research team assigned treatments and then measured the results.
Who participated
This trial was designed for adults with advanced solid tumors. Advanced solid tumors are cancers made of solid tissue that have grown or spread.
What was tested
The study looked at Asp1570 taken by itself, which is called monotherapy. It also looked at Asp1570 taken together with pembrolizumab, standard therapies, or both. Pembrolizumab is a treatment used in some study groups, and standard therapies are the usual treatments used for the condition.
Study phase and goals
This was a Phase 1/2 trial. Phase 1/2 studies are early trials that first focus on safety and dose, and then help decide whether the treatment plan should be studied further. The brief summary says the study aimed to determine the safety and tolerability of Asp1570 as monotherapy and in combination with pembrolizumab and/or standard therapies. It also aimed to find the RP2D, or recommended Phase 2 dose, and/or the MTD, or maximum tolerated dose.
What was measured
The main outcome was safety variables. These included dose-limiting toxicities, adverse events, changes from baseline in laboratory tests, vital signs, and ECG results. “Baseline” means the starting point before treatment begins. An ECG is a test that records the heart’s electrical activity.
Study status and size
The trial status is listed as completed. It enrolled 310 participants.